144 related articles for article (PubMed ID: 33893877)
1. Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers.
Thuo N; Polay M; Leddy AM; Ngure K; Chatterhee P; Gandhi M; Amico KR
AIDS Behav; 2021 Nov; 25(11):3617-3629. PubMed ID: 33893877
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
3. Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.
Mujugira A; Karungi B; Mugisha J; Nakyanzi A; Nampewo O; Naddunga F; Kamusiime B; Nsubuga R; Nyanzi KR; Muwonge TR; Wyatt MA; Ware NC; Gandhi M; Haberer JE
J Int AIDS Soc; 2024 May; 27(5):e26255. PubMed ID: 38695107
[TBL] [Abstract][Full Text] [Related]
4. MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya.
Mantell J; Franks J; Zerbe A; Lamb MR; Reed DM; Omollo D; Lahuerta M; Naitore D; El-Sadr WM; Agot K
BMJ Open; 2022 Nov; 12(11):e064037. PubMed ID: 36332953
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
6. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
[TBL] [Abstract][Full Text] [Related]
7. Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial.
Drain P; Ngure K; Mugo N; Spinelli M; Chatterjee P; Bacchetti P; Glidden D; Baeten J; Gandhi M
JMIR Res Protoc; 2020 Apr; 9(4):e15029. PubMed ID: 32238341
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
Agot K; Taylor D; Corneli AL; Wang M; Ambia J; Kashuba AD; Parker C; Lemons A; Malahleha M; Lombaard J; Van Damme L
AIDS Behav; 2015 May; 19(5):743-51. PubMed ID: 25100053
[TBL] [Abstract][Full Text] [Related]
9. Acceptability and Feasibility of Pharmacy-Based Delivery of Pre-Exposure Prophylaxis in Kenya: A Qualitative Study of Client and Provider Perspectives.
Roche SD; Wairimu N; Mogere P; Kamolloh K; Odoyo J; Kwena ZA; Bukusi EA; Ngure K; Baeten JM; Ortblad KF
AIDS Behav; 2021 Dec; 25(12):3871-3882. PubMed ID: 33826022
[TBL] [Abstract][Full Text] [Related]
10. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
Kimani M; van der Elst EM; Chirro O; Wahome E; Ibrahim F; Mukuria N; de Wit TFR; Graham SM; Operario D; Sanders EJ
PLoS One; 2021; 16(1):e0244226. PubMed ID: 33465090
[TBL] [Abstract][Full Text] [Related]
11. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
[TBL] [Abstract][Full Text] [Related]
12. Acceptability and feasibility of long-term, real-time electronic adherence monitoring of HIV pre-exposure prophylaxis (PrEP) use among young women in Kenya: A mixed methods study.
Ogello VA; Rono BK; Ngure K; Sedah E; Thuo NB; Musinguzi N; Baeten JM; Bukusi EA; Mugo NR; Haberer JE
PLoS One; 2024; 19(3):e0299168. PubMed ID: 38451884
[TBL] [Abstract][Full Text] [Related]
13. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir Urine Assay to Monitor Adherence to HIV Pre-exposure Prophylaxis.
Moorthy GS; Lalley-Chareczko L; Koenig HC; Zuppa AF
Curr Clin Pharmacol; 2020; 15(2):102-104. PubMed ID: 31713497
[TBL] [Abstract][Full Text] [Related]
15. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
[TBL] [Abstract][Full Text] [Related]
16. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
[TBL] [Abstract][Full Text] [Related]
17. Provider-client rapport in pre-exposure prophylaxis delivery: a qualitative analysis of provider and client experiences of an implementation science project in Kenya.
Omollo V; Roche SD; Mogaka F; Odoyo J; Barnabee G; Bukusi EA; Katz AWK; Morton J; Johnson R; Baeten JM; Celum C; O'Malley G
Sex Reprod Health Matters; 2022 Dec; 30(1):2095707. PubMed ID: 36169648
[TBL] [Abstract][Full Text] [Related]
18. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study.
Wheeler DP; Fields SD; Beauchamp G; Chen YQ; Emel LM; Hightow-Weidman L; Hucks-Ortiz C; Kuo I; Lucas J; Magnus M; Mayer KH; Nelson LE; Hendrix CW; Piwowar-Manning E; Shoptaw S; Watkins P; Watson CC; Wilton L
J Int AIDS Soc; 2019 Feb; 22(2):e25223. PubMed ID: 30768776
[TBL] [Abstract][Full Text] [Related]
19. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
[TBL] [Abstract][Full Text] [Related]
20. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
